Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Allergan Plc (AGN US)
Watchlist
90
Analysis
Health Care
•
United States
Allergan plc manufactures specialty pharmaceuticals. The Company develops, manufactures and distributes generic, brand and over-the-counter products. Allergan offers its pharmaceutical drugs around the world.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
09 Feb 2017 01:14
Trump Health Effect: What Is Next for the Consumer Health Industry Under Trump's Leadership?
While the US consumer health industry will remain a strong centre for investment, development and technology innovation in 2017 and is expected to...
Euromonitor International Ltd.
3.3k Views
Share
bullish
•
Thematic (Sector/Industry)
•
30 Jan 2017 05:50
Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
AML represents one of the largest hematologic cancer populations with one of the worst survival rates. Global prevalence is expected to increase at...
Dion Stéfan Büchner M.D., FCAP
564 Views
Share
bullish
•
Allergan Plc
•
24 Jan 2017 05:03
SEC and Drugmaker Allergan Reach Settlement over M&A Disclosure Violations
The U.S. Securities and Exchange Commission and drugmaker Allergan Plc (AGN US) settled claims that Allergan failed to disclose negotiations with...
Dechert LLP
443 Views
Share
bullish
•
Thematic (Sector/Industry)
•
15 Jan 2017 11:34
Cybercriminals and Activists Scale up Their Attacks – Who's at Risk and Why?
Distributed denial of service (DDoS) attacks have significantly increased in size, carried out by threat actors exploiting internet of things (IoT)...
Control Risks
389 Views
Share
bullish
•
Thematic (Sector/Industry)
•
19 Dec 2016 15:09
2017 Asset Allocation Outlook – Part 2: Trump Reflation Euphoria to Fade?
The overwhelming investor consensus a year ago was for further EM/commodity downside amid deflation fears - this year it is a USD secular bull and...
Sean Maher
412 Views
Share
First
Previous
2
3
4
5
6
7
8
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x